We are live on ! Find out more
CALA

Calithera Biosciences, Inc
CALA

Delisted

CALA was delisted on the 1st of February, 2023.

Back to rankings

23 hedge funds and large institutions have $5.01M invested in Calithera Biosciences, Inc in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

5% more funds holding

Funds holding: 22 → 23 (+1)

0% less capital invested

Capital invested by funds: $5.02M → $5.01M (-$18.2K)

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCMG
TSP Capital Management Group
New Jersey
+$107K
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.2K
3
ACP
Arcus Capital Partners
Georgia
+$597
4
Morgan Stanley
Morgan Stanley
New York
+$41

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$225K
2
Renaissance Technologies
Renaissance Technologies
New York
-$114K
3
Primecap Management
Primecap Management
California
-$32K
4
TRCT
Tower Research Capital (TRC)
New York
-$8K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.55K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$1.52M – – –
Primecap Management
2
Primecap Management
California
$1.31M -$32K -13,400 -3%
Citadel Advisors
3
Citadel Advisors
Florida
$650K -$1.01K -421 -0.2%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$505K – – –
BlackRock
5
BlackRock
New York
$273K -$442 -185 -0.2%
Renaissance Technologies
6
Renaissance Technologies
New York
$218K -$114K -47,760 -42%
Vanguard Group
7
Vanguard Group
Pennsylvania
$154K -$225K -94,048 -67%
TCMG
8
TSP Capital Management Group
New Jersey
$146K +$107K +44,750 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$95K -$165 -69 -0.2%
JP Morgan Chase
10
JP Morgan Chase
New York
$79K +$10.2K +4,260 +21%
State Street
11
State Street
Massachusetts
$35.2K – – –
Wells Fargo
12
Wells Fargo
California
$12.3K -$2.61K -1,094 -22%
FCA
13
FinTrust Capital Advisors
South Carolina
$3.92K – – –
Morgan Stanley
14
Morgan Stanley
New York
$2.27K +$41 +17 +3%
CAS
15
Coppell Advisory Solutions
Texas
$2.2K +$1.61K +675 New
CASC
16
Coppell Advisory Solutions Corp
Texas
$2.2K +$1.61K +675 New
Group One Trading
17
Group One Trading
Illinois
$2.15K -$2.47K -1,033 -61%
Bank of America
18
Bank of America
North Carolina
$1.76K -$2 -1 -0.2%
UBS Group
19
UBS Group
Switzerland
$1.05K – – –
ACP
20
Arcus Capital Partners
Georgia
$815 +$597 +250 New
TC
21
Truvestments Capital
Florida
$170 – – –
Citigroup
22
Citigroup
New York
$46 – – –
QC
23
Quent Capital
New York
$7 – – –
TRCT
24
Tower Research Capital (TRC)
New York
– -$8K -2,647 Closed
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
– -$3.55K -1,206 Closed

CALA Hedge Fund Activity: Q4 2022 in Review

23 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q4 2022, worth a combined $5.01M — down 0.36% from $5.02M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CALA positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 9 trimmed.

The largest buyer was TSP Capital Management Group, opening a new position worth an estimated $107K. The largest seller was Vanguard Group, cutting an estimated $225K.

  • 23 institutional investors held Calithera Biosciences, Inc (CALA) as of Q4 2022, up from 22 in Q3 2022.
  • Funds reported $5.01M of Calithera Biosciences, Inc stock for Q4 2022, down 0.36% quarter-over-quarter.
  • 4 funds opened new Calithera Biosciences, Inc positions in Q4 2022 and 3 closed out, a net change of +1 holder.
  • The largest Calithera Biosciences, Inc buyer in Q4 2022 was TSP Capital Management Group, an estimated $107K added.
  • The largest Calithera Biosciences, Inc seller in Q4 2022 was Vanguard Group, an estimated $225K sold.

Based on aggregated 13F filings for Q4 2022.